Propargyl-PEG9-amine

Description

Attogene Fluorescent Universal Lateral Flow Assay Kits are a convenient ready-to-use kit for quick and cost-effective development of a fluorescent lateral flow dipstick assay for detection of DNA and RNA products.

Fluorescent lateral flow assays can be 2-100 fold more sensitive that gold based lateral flow tests.  Europium dyed polystyrene beads conjugated to streptavidin

Formats (fluorescent broad range UV light excitation range of 300nm to 400nm, 610nm emission) Streptavidin conjugate pad):

• • Detectable using a black light such as a black light UV flashlight or fluorescent lateral flow reader.
• • Detection of nucleic Acid (DNA or RNA) requires the use of a biotin and FAM-labelled primer during amplification. 
• • Test line: anti-FITC/FAM
• • Control Line: Biotin
• • Multiplex detection of nucleic Acid (DNA or RNA) requires the use of a biotin, FAM and Dig labelled primers during amplification.:
• • Test Line #1: anti FITC/FAM, Line #2: anti-Dig, Line #3 Biotin.

---

Inquire about custom configurations: sales@attogene.com. 

For example, this product can be configured with alternative/custom streptavidin fluorescent particles.

---

Kit Components 

• 50 -4.5mm Fluorescent Lateral Flow Dipsticks
• 10 mL Sample assay running buffer

Features & Benefits

• Can be used for development of a lateral flow assay for detection of a variety of different molecules such as amplified DNA products from PCR, LAMP and RPA reactions.
• No need to stripe capture antibodies
• No expensive equipment required (Black Light)
• Cost-effective way to screen for further downstream lateral flow assay development.

Description

Specifications

Clone	IHC409
Source	Mouse Monoclonal
Positive Control	Colon, Colon Carcinoma
Dilution Range	1:200

MutL Homolog 1 (MLH1) is a protein involved in the mismatch-repair pathway. This protein is commonly associated with hereditary non-polyposis colorectal cancer, as the MLH1 gene is frequently mutated in patients with this cancer. Studies have shown MLH1 to be deficient in a high percentage of patients with microsatellite instability, as well as endometrial and ovarian cancers. Use of Anti-MLH1 is optimized when paired in an IHC panel with MSH6, MSH2, and PMS2. Anti-MLH1 is useful in the detection of MLH1 in a number of normal and neoplastic tissues, and for identifying a loss of MLH1 in tumors that are microsatellite-unstable.